

# **Anti-Complement C5 Reference Antibody (lendalizumab)**

Recombinant Antibody Catalog # APR10841

#### **Specification**

### Anti-Complement C5 Reference Antibody (lendalizumab) - Product Information

Application FC, Kinetics, Animal Model Primary Accession P01031

Reactivity
Clonality
Isotype
Calculated MW

P01031
Human
Monoclonal
IgG2SA
145 KDa

### Anti-Complement C5 Reference Antibody (lendalizumab) - Additional Information

Target/Specificity Complement C5

**Endotoxin** 

< 0.001EU/ μg, determined by LAL method.

**Conjugation** Unconjugated

**Expression system** 

CHO Cell

#### **Format**

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

### Anti-Complement C5 Reference Antibody (lendalizumab) - Protein Information

Name C5

Synonyms CPAMD4

#### **Function**

Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled.

**Cellular Location** 

Secreted.


### **Anti-Complement C5 Reference Antibody (lendalizumab) - Protocols**




Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- <u>Immunohistochemistry</u>
- <u>Immunofluorescence</u>
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

## Anti-Complement C5 Reference Antibody (lendalizumab) - Images



Anti-Complement C5 Reference Antibody (lendalizumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%



The purity of Anti-Complement C5 Reference Antibody (lendalizumab)is more than 95% ,determined by SEC-HPLC.